Who owns ELIEM THERAPEUTICS INC?
- Ticker: CLYM
- CUSIP Number: 28658r106
Tip: Access positions for across all investors
Analyze quarterly positions in Eliem Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Eliem Therapeutics stock
Who bought or sold ELIEM THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 11M | $77M | 0% | Mar 2026 |
|
| MPM Oncology Impact Management | 2.6M | $18M | -3% | Mar 2026 |
|
| Braidwell | 1.5M | $11M | 100% | Mar 2026 |
|
| Vanguard Group | 1.3M | $5.4M | 2% | Dec 2025 |
|
| Dr. Jeffrey R. Jay, M.D. | 1.3M | $9.1M | 36% | Mar 2026 |
|
| Affinity Asset Advisors | 1.3M | $5.2M | 0% | Dec 2025 |
|
| Millennium Management | 1.3M | $8.7M | 331% | Mar 2026 |
|
| Vanguard Capital Management | 1.2M | $8.1M | 100% | Mar 2026 |
|
| Kynam Capital Management | 1.0M | $6.9M | -2% | Mar 2026 |
|
| Driehaus Capital Management | 601k | $2.4M | 100% | Dec 2025 |
|
| ADAR1 Capital Management | 598k | $4.1M | -58% | Mar 2026 |
|
| Susquehanna International | 445k | $1.8M | 213% | Dec 2025 |
|
| Nan Fung Trinity | 421k | $2.9M | -9% | Mar 2026 |
|
| Sphera Funds Management | 419k | $2.9M | -55% | Mar 2026 |
|
| BlackRock | 402k | $2.8M | 3% | Mar 2026 |
|
| Citadel Advisors | 346k | $2.4M | 45% | Mar 2026 |
|
| Renaissance Technologies | 321k | $1.3M | -40% | Dec 2025 |
|
| Geode Capital Management | 313k | $2.1M | 1% | Mar 2026 |
|
| Two Sigma Investments | 311k | $2.1M | -45% | Mar 2026 |
|
| Marshall Wace | 304k | $1.2M | 32% | Dec 2025 |
|
| TD Asset Management | 250k | $1.7M | 2% | Mar 2026 |
|
| Morgan Stanley | 234k | $1.6M | 58% | Mar 2026 |
|
| Longaeva Partners | 218k | $1.5M | 100% | Mar 2026 |
|
| Jane Street | 186k | $1.3M | -1% | Mar 2026 |
|
| Bridgeway Capital Management | 159k | $637k | 46% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 159k | $1.1M | 100% | Mar 2026 |
|
| Manufacturers Life Insurance Company | 156k | $1.1M | 11% | Mar 2026 |
|
| Goldman Sachs Group | 150k | $1.0M | -33% | Mar 2026 |
|
| Seven Fleet Capital Management | 131k | $895k | 71% | Mar 2026 |
|
| State Street Corporation | 129k | $516k | 25% | Dec 2025 |
|
| Northern Trust | 125k | $499k | -1% | Dec 2025 |
|
| Botty Investors | 121k | $832k | 0% | Mar 2026 |
|
| Peapod Lane Capital | 109k | $740k | -81% | Mar 2026 |
|
| Dimensional Fund Advisors | 104k | $715k | 100% | Mar 2026 |
|
| Boothbay Fund Management | 92k | $632k | 100% | Mar 2026 |
|
| 683 Capital Management | 90k | $617k | -55% | Mar 2026 |
|
| UBS Group | 86k | $589k | 21% | Mar 2026 |
|
| Persistent Asset Partners | 72k | $495k | 684% | Mar 2026 |
|
| Barclays | 62k | $247k | 150% | Dec 2025 |
|
| LPL Financial | 60k | $414k | -3% | Mar 2026 |
|
| Point72 Asset Management | 59k | $405k | -92% | Mar 2026 |
|
| Brevan Howard Capital Management | 57k | $388k | 100% | Mar 2026 |
|
| Hudson Bay Capital Management | 55k | $373k | 12% | Mar 2026 |
|
| Bank of America Corporation | 53k | $363k | 100% | Mar 2026 |
|
| Squarepoint Ops | 43k | $294k | 100% | Mar 2026 |
|
| Hrt Financial | 37k | $254k | 100% | Mar 2026 |
|
| XTX Topco | 35k | $139k | 19% | Dec 2025 |
|
| Qube Research & Technologies | 35k | $138k | -5% | Dec 2025 |
|
| Cantor Fitzgerald, L. P. | 30k | $206k | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 29k | $200k | 5578% | Mar 2026 |
|
| Arrowpoint Investment Partners | 25k | $168k | 100% | Mar 2026 |
|
| Springbok Capital Management | 20k | $80k | -51% | Dec 2025 |
|
| Fox Run Management | 19k | $126k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 17k | $114k | -80% | Mar 2026 |
|
| William Blair $ Company | 12k | $82k | 9% | Mar 2026 |
|
| Diametric Capital | 11k | $77k | 100% | Mar 2026 |
|
| JustInvest | 11k | $77k | 1% | Mar 2026 |
|
| Virtu Financial | 11k | $43k | 100% | Dec 2025 |
|
| Vanguard Global Advisers | 10k | $69k | 100% | Mar 2026 |
|
| Balyasny Asset Management | 7.0k | $48k | -51% | Mar 2026 |
|
| FMR | 6.3k | $25k | -11% | Dec 2025 |
|
| Citigroup | 5.8k | $40k | 100% | Mar 2026 |
|
| Tower Research Capital | 3.4k | $13k | -75% | Dec 2025 |
|
| Advisor Group Holdings | 600.00 | $2.4k | -97% | Dec 2025 |
|
| NISA Investment Advisors | 573.00 | $3.9k | 0% | Mar 2026 |
|
| Fortitude Family Office | 92.00 | $629.997600 | 100% | Mar 2026 |
|
| Russell Investments | 79.00 | $540.999900 | 100% | Mar 2026 |
|
| Royal Bank of Canada | 79.00 | $0 | -89% | Mar 2026 |
|
| SRS Capital Advisors | 51.00 | $110.001900 | 100% | Mar 2026 |
|
| CWM | 29.00 | $0 | -73% | Dec 2025 |
|
| Deutsche Bank Aktiengesellschaft | 1.00 | $7.000000 | 0% | Mar 2026 |
|
Who sold out of Eliem Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Ameriprise Financial | Dec 2025 | 140k | $558k |
| Diadema Partners | Sep 2025 | 137k | $274k |
| Two Sigma Advisers | Dec 2025 | 125k | $499k |
| Bluefin Capital Management | Sep 2025 | 60k | $121k |
| Citizens Financial Group | Dec 2025 | 28k | $113k |
| Hsbc Holdings | Dec 2025 | 25k | $99k |
| Jpmorgan Chase & Co | Sep 2025 | 22k | $44k |
| Susquehanna Portfolio Strategies | Sep 2025 | 18k | $37k |
| Chicago Partners Investment | Dec 2025 | 11k | $55k |
| Scientech Research | Dec 2025 | 10k | $42k |
| Harbour Investments | Dec 2025 | 2.0k | $8.0k |
| Advisory Services Network | Sep 2025 | 32.00 | $64.000000 |